Highest-materiality recent filing
Ilan Ganot resigned from Class III effective 4:00 p.m. ET on April 10, 2026.
40 participants dosed; SGT-003 well tolerated with steroid-only immunomodulation regimen.
Solid Biosciences raises ~$240M in private placement; prelim cash ~$188M
Gross proceeds ~$240M from 14.97M shares at $5.61 and 27.81M pre-funded warrants at $5.609.
Cash, cash equivalents and available-for-sale securities: $236.1M as of Sep 30, 2025; runway into H1 2027.
SLDB stockholders approve doubling authorized shares to 240M and adding 9M shares to equity plan
Authorized common stock increased from 120M to 240M via Certificate of Amendment filed June 12, 2025.
Solid Biosciences ups ATM offering capacity to $85M; $10.5M already sold
Filed prospectus supplement on May 15, 2025 to increase ATM offering from $75M to $85M.
Solid Biosciences reports 110% avg microdystrophin expression from SGT-003 Phase 1/2 trial
First three participants showed average 110% microdystrophin expression by western blot and 78% dystrophin-positive fibers at Day 90.
Solid Biosciences prices $200M underwritten offering; extends cash runway into first half 2027
Priced $200M underwritten offering expected to close Feb 19, 2025; net proceeds to fund R&D for SGT-003 and other candidates.
Solid Biosciences prices $200M public offering of common stock and pre-funded warrants
Priced public offering of 35.7M shares at $4.03/share and pre-funded warrants for 13.9M shares at $4.029 each; gross proceeds ~$200M.
Adam Koppel and Rajeev Shah resigned from the Board effective June 11, 2024; no disagreement cited.
Adam Koppel notified Solid Biosciences Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), effective as of June 11, 2024.
Rajeev Shah notified the Company of his decision to resign as a member of the Board, effective as of June 11, 2024.
Max materiality 0.85 · Median 0.72 · Most common event other_material